for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. House panel to examine approval, pricing of Alzheimer's drug from Biogen

June 25 (Reuters) - A U.S. House panel said on Friday it would examine the approval and pricing of Biogen Inc’s Alzheimer’s drug, Aduhelm.

Biogen had announced a list price of $56,000 per year for the drug. (Reporting by Dania Nadeem in Bengaluru; Editing by Arun Koyyur)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up